Drug Trial Radar · NCT07889245
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Aug 24, 2028
Study completion Dec 24, 2028
Sponsor
- Lead sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic cardiovascular disease (diagnosed or at increased risk).
Conditions
- sHTG
- HTG With ASCVD (Diagnosed or at Increased Risk)
Interventions
FXR0906 injectionDrug
2 doses of FXR0906 (dose 1 ) by subcutaneous (sc) injection
FXR0906 injectionDrug
2 doses of FXR0906 (dose 2 ) by subcutaneous (sc) injection
FXR0906 injectionDrug
2 doses of FXR0906 (dose 3 ) by subcutaneous (sc) injection
PlaceboDrug
The placebo is normal saline (0.9%) and 2 doses of volume matched placebo will be administrated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- percent change from baseline at week 24 in fasting triglycerides(TG)Time frame: baseline, week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.